Minerva Neurosciences Study update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everybody. It's really a pleasure and honor to have you here on behalf of the Minerva team. Most of my colleagues are here, so after these presentations, when we have something to eat afterwards, don't hesitate to go to see them, to speak with them. It's already an honor to have you here, to really, I think, present you something which is very important. As you know, since 70 years, people have tried hard in order to improve negative symptoms of patients suffering with schizophrenia. I think here today, we have now roluperidone, which is really, really creating some hope for patients. As you know, we are all here in order to come up with better treatments for patients. This is what we will go through today, to give you an update about where we are and where we are going.
If it is moving, it is moving. Because we are a public company, I have always to show this slide. I think it's just to mention that we are a public company, and if you want to know more, you have to go to our SEC filings. I have really the great pleasure to have with us three persons who have been extremely important for the space. I have the honor to have Dr. Strauss, Greg, yes, because we are working together since quite long, yes, so allow me to call you Greg, yes. Greg, you will see, has worked on our data, has analyzed our data, and he has obviously a very broad knowledge about the space. I will not go more into the details because his CV is too long, and he will present his research when he will speak.
The second person could not make it today. It is Dr. Brian Kirkpatrick, and Brian will also speak. Brian is really, I think this is really amazing because Brian is really, really an incredible researcher, but he kept really the contact with patients. He sees patients on a daily basis, and he will tell us about how his patients are looking like, how he sees his patients. I mean, we are targeting with roluperidone in his clinical practice. Last but not least, we have Dr. Correll, yes, and Christoph is, as you know, no need to present him. He's an amazing person, and he has really contributed a lot to the space. We will have obviously a Q&A session, so you can ask all the questions to my three colleagues here speaking. What we will address today is a quite large program, yes.
First, I will give you a refreshment about roluperidone, where we are with roluperidone. Also, a quick update on the C19 study because the study is ongoing. Afterwards, I hand over to Greg, to Dr. Strauss, who will speak about how important primary negative symptoms are. Yes. We're not going into the details about primary, secondary negative symptoms because Dr. Strauss will speak a lot about it, and he will explain how important they are in order to give some hope to patients. Dr. Kirkpatrick will speak about, again, as I said, his view on our patients, why these patients are not keen to relapse or have limited relapses, and how he sees his patients in his clinical practice.
I will go quickly through some new analysis because we continue to work on our data, just to better understand the data, to better characterize the patient population, to better characterize roluperidone. You will see we have quite exciting data. We have here in the room Jonathan Rabinowitz and Michael Davidson, who have worked on this. If you have questions, they are more than happy to answer the questions. Afterwards, I will conclude with giving you a flavor about what is a market opportunity. Afterwards, we open for Q&A.
I wanted also to mention that we have the chance to have my friend, Frank, who is here, yes, because Frank has been from the beginning of this journey. He is really guiding us through how to bring over the message to the FDA, to the regulator, of this paradigm shift, yes, because we are speaking here about a paradigm shift. I hope that at the end of the presentation, you will see that indeed what we are doing here is a paradigm shift. As you know, when you are changing something in clinical practice, when you are coming up with new ideas, it is always a little bit challenging, but we are getting there because I think roluperidone could really be the first drug approved for negative symptoms. Very quickly, a few words about what we are doing here. Just to reemphasize the fact that negative symptoms are really central.
It is really central when we are thinking about giving a solution or treating or providing a treatment for patients with schizophrenia. I will not focus on all this primary, secondary negative symptoms because I think Greg will cover this much better than me. I wanted to focus just on the figure on the top right, by the way, published by Dr. Correll. Just to mention that, and it is maybe obvious for everybody, but it is important, you have three types of symptoms when you are dealing with patients suffering from schizophrenia. You have the positive symptoms, materialized or shown by these green lines. You have some acute phases of positive symptoms, what we call relapses of positive symptoms. Afterwards, when the disease is aging, these positive symptoms are less bothering, are less frequent, are really no longer really a big problem.
This is what we are currently treating with antipsychotics, yes? We are really focusing on treating positive symptoms. You see that we have two types of other symptoms, the cognitive deficit, which is materialized with the blue line here. This is a type of symptoms which are present all along the life of the patient. We have negative symptoms in the brown line. Again, you will hear a lot about negative symptoms. Just what I wanted to mention on this slide, look, what Christoph put is a level where disability starts to kick in, yes? When you see when disability starts to kick in, it is really when negative symptoms are becoming a real problem.
Really, I think it is very clear now to everybody that if we want to give a chance for patients to have a decent family life, to have a small job, we need to find a solution for negative symptoms. Just to make my case here, yes? We know very well, it is very well described in the literature, and there are some references here at the bottom. It is really negative symptoms, not the positive symptoms, which are really the primary drivers of the disability in patients. This very schematic way to present things, it is clear that if you are able to improve negative symptoms, probably you are able to improve the daily functioning of these patients. You will see that in our studies, we have really always measured the daily functioning using a scale which is called the PSP scale, and obviously the improving quality of life.
I think what speaks very well here, and I am always taking this example, it is now 70 years or so that we have antipsychotics. Again, don't take me wrong, antipsychotics are very important, yes? They are very important in our ammunition in order to help these patients. But when you are looking to how many patients have a job, nothing has changed since 70 years, yes? When you see that 80%-90% of these patients have no job, compared to 4%, 5% to normal people, definitely, I mean, there is something which has to be done. Again, probably improving negative symptoms, but probably also improving primary negative symptoms is definitely important. Now, coming to roluperidone, yes? Slide shows up, it takes a little bit time. This is the pharmacology of roluperidone, and I wanted just to give you the rationale how we designed roluperidone.
The first objective was to get rid of direct dopamine blockade, yes? This was the first objective because we know that blocking dopamine is very important for antipsychotics to help to treat an acute episode of psychosis or positive symptoms. But we know also that by doing so, you are inducing a lot of side effects. We are always forgetting sometimes the side effects, but when, I think Michael showed me a recent study, the reason why patients are really willing to stop the treatment is because they are bothered with side effects. Obviously, they have also the psychotropic effects, but they are really bothered with side effects. So it is really a problem. Roluperidone has no direct blocking effect on dopamine. It is definitely modulating dopamine, and I will not go into the details because it would be too long. But definitely, it is not blocking dopamine.
The three targets we have here is serotonin. We are targeting the sub-receptors, which is called the five-HT2A receptor. It has an antagonistic activity there. The sigma-2 receptor, which is a less known pathway in the brain, but definitely, in my opinion, and based on my clinical observations, developing quite a lot of drugs in my life, the sigma activity is probably one of the key drivers of explaining why our drug is improving negative symptoms. You will see probably primary negative symptoms, and afterwards, you have also an alpha-1 adrenergic activity. So it is always difficult to say this target is doing this, but I think the combination of the three targets is definitely explaining the uniqueness of roluperidone. Last but not least, we have done a lot of work to better understand what is going on also, for example, in terms of nerve growth factors.
For the moment, it is preclinical, but I mean, it's very, very compelling data. We can demonstrate that roluperidone is inducing a huge increase in transcription of BDNF and GDNF, and also the release of BDNF and GDNF. Think one second, I mean, these nerve growth factors are really, really important in neuroplasticity, to restore neuroplasticity. This is what is about roluperidone, and it has been designed on purpose. Now, let's see if, I mean, all these hypotheses are translating into what we have seen in clinical practice. Here, it's very summarized, just because, I mean, the objective is not to go through all the data. It's more important that my colleagues are speaking afterwards. What you can see in terms of efficacy, so in all the two studies, we have run two studies, which one is called C03 study, the other one C07 study.
We have measured negative symptoms using the PANSS scale, which is a gold standard. When you're looking to the negative score, which has been proposed by Professor Marder, which is called the NSFS score, you see that the first study, the C03 study- No-brainer. I mean, 64 milligram showed a very, very strong difference compared to placebo after 12 weeks of treatment in monotherapy. Keep in mind that here, the patients are not staying on antipsychotics. These are really treated in monotherapy for 12 months. What you can see is that in the C07 study, we still have for 64 milligram, which was the highest dose we tested, a P-value, which is obviously going down because a larger study, more clinical sites, but we have still a P-value.
What we also measured, because this is important, and we will hear a lot about functioning, we measured functioning using the PSP scale. What you can see here, again, in the two studies, we could demonstrate that indeed, looking to daily activities, because PSP is a very practical scanner, so looking to daily activity, indeed, you can see that these patients are, once they're improving the negative symptoms, they're also improving their daily functioning. Obviously, last but not least, what is important, is this drug safe in terms of relapses, when you give it in monotherapy? Because again, the paradigm shift here is to say there is a subpopulation who does not need continuous treatment with an antipsychotic. Obviously, the pharmacology of roluperidone might help, but what happens in terms of relapses?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
9 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
